Exploring Novel Biological Rationales for the Design of Next-Generation Combination Therapies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5193
Special Issue Editors
Interests: chemotherapy; immunotherapy; preclinical models; tumor microenvironment; combination therapies; type I interferons; dendritic cells; natural compounds; microbiota
Interests: immunogenic anticancer therapies; cancer evolution; cancer stem cells; immune escape; preclinical mod-els; tumor microenvironment; type I interferons; combination anticancer therapies
Interests: tumor-specific active immunotherapy; immuno-checkpoint inhibitors; tumor-specific CTLs; immunomodulation; combination anticancer therapies; real-world evidence in cancer therapy
Special Issue Information
Dear Colleagues,
Combination therapy, a therapeutic strategy originating from the combination of two or more therapeutic agents with different mechanisms of action, represents a cornerstone of cancer treatment. Combinations of surgery, radiation therapy, chemotherapy, and immunotherapies are increasingly applied in almost all cancer types with variable clinical benefit. Despite advancements in the field, drugs are mostly combined without a deep knowledge of their off-target effects, often resulting in limited treatment efficacy. Additionally, strong preclinical rationale for combination is frequently missing. The purpose of this Special Issue is to highlight rationale-based preclinical and clinical original research articles evaluating combinations of standard-of-care treatments and experimental approaches or compounds, including natural compounds, in all cancer types. Combinations of repurposed drugs with standard or experimental treatments are also encouraged.
Dr. Laura Bracci
Dr. Antonella Sistigu
Dr. Pierpaolo Correale
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chemotherapy
- immunotherapy
- radiotherapy
- immunomodulation
- drug repurposing
- natural compounds
- combination therapies
- biomarkers
- preclinical models
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
